Written by ι Stock Market Media Group Staff — May 21, 2013
In a series of articles to introduce Plandaí Biotechnology, Inc.’s (OTCQB: PLPL) three highly bioavailable products, the second of three introduces what could be the go-to solution for the common cold. All of Plandaí’s extracts will be individually labeled and marketed under the Phytofare™ brand.
Much like its first product, Phytofare™ Catechin Extract, Plandaí’s Phytofare™ Limonoid Glycoside Complex will hit the market and offer the company’s customers a higher absorption rate than the market’s current products can deliver. The citrus derived Limonoid Glycoside Complex is a unique product that utilizes the entire lemon fruit including juice, pith, peel, and pulp from where all the soluble phytonutrients are recovered.
It is an extract that is formulated to contain any or all of vitamins A & C, bioflavonoids, (Hesperidin and Rutin), limonoids (limonin and nomilin), and numerous minerals, including potassium and pectin. The resulting complex has been scientifically proven to improve and maintain capillary integrity; fight infections, relieve the common cold and flu symptoms; reduce inflammation, and decrease the healing time of sports-related injuries.
In the early 1960’s, the US Olympic Team used Citrus Bioflavonoids for track and field athletes. They found that muscle pulls were virtually eliminated and injuries healed twice as fast. With the improved healing times from using a Citrus Complex, athletes can train longer and harder, yielding improved performance results.
While research into commercializing a citrus complex containing limonoids has stalled in the past, Plandaí intends to be the first to enter this market with a high-purity and water-soluble citrus complex once supporting human clinical trials are completed.
Just as with the company’s first product, Phytofare™ Catechin Extract, Plandaí will use its proprietary hydrodynamic sheering process where live plant-materials are converted at the molecular level during extraction into a nano-particle sized isomeric structure that resembles that found in human tissues.
Plandaí’s CEO Roger Duffield says that many drug compounds are synthesized plant analogs. “While botanical material can have tremendous curative properties, it generally has poor bioavailability or low absorption in human tissues. This is because human tissues have a different molecular structure than plant matter.”
Plandaí stresses that a synthetic drug tries to recreate the beneficial elements using a synthesized molecule that has greater bioavailability. Unfortunately, these synthetics often have adverse side effects and, over time, can result in drug-resistant strains of the disease.
The CEO says the company’s patented technology allows Plandaí to take specific types of live plant material and unzip the molecules, releasing all of the phytonutrients, and then rearrange the isomeric properties of the molecule so that it mimics the 50/50 ratio commonly found in human tissues. Duffield says, “Simultaneously, we’re able to take out any undesirable elements and reduce the particles to nano-size.”
What this means is that Plandaí is able to tailor design the living molecule to maximize the phytonutrient properties and absorption. Documented research shows that Phytofare™ is clinically proven to have far superior absorption. So, where most phytonutrients are poorly absorbed in humans, often less than 10 percent, Plandaí’s products are 60-80% absorbed.
The CEO adds, “The key for us is using live plant materials. From the moment of harvest, we maintain the material at an optimal temperature and then begin the extraction process within the hour. This ensures that we are releasing and capturing live anti-oxidants, resulting in a product that is 100% pure bioactive. We believe that this technology is the foundation for creating a whole new family of drugs that can treat a multitude of diseases and conditions, safely and affordably using naturally-derived extracts.”
In addition, Plandaí’s unique extraction process allows for the systematic removal of any undesirable phytonutrient resulting in a product that is significantly more pure and concentrated than competing botanicals. In an industry where more than $65-billion is wasted on wellness products due to poor bioavailability, the market should welcome Plandaí Biotechnology and its Phytofare™ brand that could deliver three new products that are six to eight times more bioavailable than the market is currently giving them.